{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:20:51Z","timestamp":1765315251841,"version":"3.46.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.7759\/cureus.98830","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:19:29Z","timestamp":1765315169000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe, Resistant Generalized Pustular Psoriasis-Associated Inflammatory Syndrome Successfully Treated With Adalimumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Evangelos","family":"Bourousis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Triantafyllia","family":"Kotzamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despoina N","family":"Maritsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00664-x","article-title":"The prevalence and disease characteristics of generalized pustular psoriasis","volume":"23","author":"Zheng M","year":"2022","unstructured":"Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022, 23:5-12. 10.1007\/s40257-021-00664-x","journal-title":"Am J Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12395","article-title":"The update of treatment strategies in pediatrics with generalized pustular psoriasis in China","volume":"7","author":"Chen Y","year":"2023","unstructured":"Chen Y, Xiang X, Wang Z, Miao C, Xu Z. The update of treatment strategies in pediatrics with generalized pustular psoriasis in China. Pediatr Investig. 2023, 7:191-8. 10.1002\/ped4.12395","journal-title":"Pediatr Investig"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01084.x","article-title":"Generalized pustular psoriasis in childhood","volume":"27","author":"de Oliveira ST","year":"2010","unstructured":"de Oliveira ST, Maragno L, Arnone M, Fonseca Takahashi MD, Romiti R. Generalized pustular psoriasis in childhood. Pediatr Dermatol. 2010, 27:349-54. 10.1111\/j.1525-1470.2010.01084.x","journal-title":"Pediatr Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis A","year":"2011","unstructured":"Onoufriadis A, Simpson MA, Pink AE, et al.. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011, 89:432-7. 10.1016\/j.ajhg.2011.07.022","journal-title":"Am J Hum Genet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0","article-title":"Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment","volume":"13","author":"Rivera-D\u00edaz R","year":"2023","unstructured":"Rivera-D\u00edaz R, Daud\u00e9n E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023, 13:673-88. 10.1007\/s13555-022-00881-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/genes14061297","article-title":"Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics","volume":"14","author":"Yang SF","year":"2023","unstructured":"Yang SF, Lin MH, Chou PC, Hu SK, Shih SY, Yu HS, Yu S. Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics. Genes (Basel). 2023, 14:1297. 10.3390\/genes14061297","journal-title":"Genes (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter A","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DM, et al.. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020, 82:161-201. 10.1016\/j.jaad.2019.08.049","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S407812","article-title":"Use of biological therapies for the management of pustular psoriasis: a new era?","volume":"16","author":"Megna M","year":"2023","unstructured":"Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L. Use of biological therapies for the management of pustular psoriasis: a new era?. Clin Cosmet Investig Dermatol. 2023, 16:1677-90. 10.2147\/CCID.S407812","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01988-0","article-title":"Spesolimab for the treatment of generalized pustular psoriasis","volume":"84","author":"Bernardo D","year":"2024","unstructured":"Bernardo D, Tha\u00e7i D, Torres T. Spesolimab for the treatment of generalized pustular psoriasis. Drugs. 2024, 84:45-58. 10.1007\/s40265-023-01988-0","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren RB","year":"2023","unstructured":"Warren RB, Reich A, Kaszuba A, et al.. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023, 189:161-9. 10.1093\/bjd\/ljad083","journal-title":"Br J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313570-severe-resistant-generalized-pustular-psoriasis-associated-inflammatory-syndrome-successfully-treated-with-adalimumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:19:30Z","timestamp":1765315170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313570-severe-resistant-generalized-pustular-psoriasis-associated-inflammatory-syndrome-successfully-treated-with-adalimumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.98830","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}